This pipeline analysis report offers detailed insights into the clinical trials landscape of the stem cell therapy for multiple sclerosis including molecules at different development stages. Moreover, the report also offers information about the therapeutic assessment of the pipeline molecules based on various segmentations including route of administration.
Overview of the stem cell therapy for multiple sclerosis
Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision, and tingling. At present, therapies available for multiple sclerosis majorly focuses on slowing the progression of the disease, whereas, symptomatic interventions determine the management of the disease. The market research analysts have predicted that with the introduction of mesenchymal stem cells therapy as one of the most promising investigational approach to treat multiple sclerosis, the global multiple sclerosis market will witness growth in the forthcoming years. it has been observed that the American cryostem and celgene cellular therapeutics have their stem cell therapy candidates for the treatment of multiple sclerosis in phase I stage of development.
According to this pipeline analysis report, most of the companies have not specified the type of multiple sclerosis their drugs are being developed for. One of the Tier 1 companies Celgene cellular therapeutics, is developing PDA-001 for RRMS as well as SPMS.
This pipeline analysis report provides a comprehensive analysis of the companies that are actively involved in the development of stem cell therapy molecules for the treatment of multiple sclerosis. In addition to offering information on the various stages of molecules developed for different indications, this pipeline analysis report also provides information about the stem cell therapy molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- American CryoStem
- Celgene Cellular Therapeutics
- Cell Cure Neurosciences
Therapeutic assessment of the stem cell therapy for multiple sclerosis by route of administration
According to our research experts, majority of stem cell therapy candidates that are currently in the pipeline are being developed as intravenous drugs. However, the RoA for several drugs that are in the early development stages are not disclosed by companies.
Key questions answered in the report include
- What are the stem cell molecules in the various development stages for multiple sclerosis?
- What are the companies that are currently involved in the development of stem cell therapy molecules for multiple sclerosis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule.
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: STEM CELL THERAPY FOR MULTIPLE SCLEROSIS: AN INSIGHT
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Mid-stage molecules (Phase I/II), 2017
- Early-stage molecule (Phase I), 2017
- Pre-clinical and discovery stage molecules, 2017
- Inactive (status unknown and terminated) molecules, 2017
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT BY ROA
PART 10: KEY COMPANIES
- Active companies: Category and parameters
PART 11: APPENDIX
- List of abbreviations
List of Exhbits
Exhibit 01: Drug approval process by US FDA
Exhibit 02: Pipeline landscape
Exhibit 03: Pipeline molecules in different developmental stages 2017
Exhibit 04: Overview: Human umbilical cord mesenchymal stem cells
Exhibit 05: Clinical trials description of Huma umbilical cord mesenchymal stem cells
Exhibit 06: Overview: Autologous adipose-derived mesenchymal cells
Exhibit 07: Clinical trials description of Autologous adipose-derived mesenchymal cells
Exhibit 08: Overview: PDA-001
Exhibit 09: Clinical trials description of PDA-001
Exhibit 10: Overview: MultiStem
Exhibit 11: Overview: MSC-NTF
Exhibit 12: Overview: AST-OPC1
Exhibit 13: Overview: NSI-777
Exhibit 14: Overview: ALLOCETRA
Exhibit 15: Overview: NeurArrest
Exhibit 16: Overview: Adult stem cell therapy
Exhibit 17: Overview: Umbilical cord-derived mesenchymal stem cells
Exhibit 18: Clinical trials description of Umbilical cord-derived mesenchymal stem cells
Exhibit 19: Overview: Autologous bone marrow-derived mononuclear stem cells
Exhibit 20: Clinical trials description of Autologous bone marrow-derived mononuclear stem cells
Exhibit 21: Pipeline molecules as per types of multiple sclerosis
Exhibit 22: Assessment by RoA
Exhibit 23: Active companies: Category and parameters 2017
Exhibit 24: Segmentation of companies 2017
Exhibit 25: Overview: American CryoStem 2017
Exhibit 26: Overview: Asterias Biotherapeutics 2017
Exhibit 27: Overview: Athersys 2017
Exhibit 28: Overview: Brainstorm Cell Therapeutics 2017
Exhibit 29: Overview: Celgene Cellular Therapeutics 2017
Exhibit 30: Overview: Cell Cure Neurosciences 2017
Exhibit 31: Overview: DaVinci Biosciences 2017
Exhibit 32: Overview: Enlivex Therapeutics 2017
Exhibit 33: Overview: Neuralstem 2017
Exhibit 34: Overview: Translational Biosciences 2017